Brainomix, an Oxford, England, UK-based medical imaging company using artificial intelligence (AI) for the fast diagnosis and treatment of stroke victims, raised £7m ($9.8m) in funding.
The round was led by Parkwalk Advisors, with participation from existing investors Chimera Partners, Oxford University Innovation Fund, and Boehringer Ingelheim Venture Fund (BIVF).
The company intends to use the funds to further commercialize its intelligent medical imaging and workflow software solutions and expand its market penetration around the world.
Led by Dr Michalis Papadakis, CEO, Brainomix is advancing e-ASPECTS, a flagship software solution that uses AI to provide a fast and standardized assessment of stroke patient CT scans, supporting treatment decisions by medical professionals.
The software works by automating the clinically-validated Alberta Stroke Program Early CT Score (ASPECTS) method.